timothy sykes logo
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset Thumbnail
ADD US ONG Google News

Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset

JACK KELLOGG•UPDATED MAR. 9, 2026, 10:18 AM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

Relmada Therapeutics Inc.’s stock surged 34.61% on positive sentiment driven by breakthrough clinical trial results.

Candlestick Chart

Live Update At 10:18:09 EST: On Monday, March 09, 2026 Relmada Therapeutics Inc. stock [NASDAQ: RLMD] is trending up by 34.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Relmada Therapeutics, known by its ticker RLMD, continues to keep the financial world on its toes with remarkable fluctuations. Presently, its financial backbone is under a magnifying lens with the asset NDV-01 promising hope in the cancer treatment landscape. Showcasing an enterprise value of roughly $14.15M and a unique price-to-book ratio of 34.48, the company’s valuation metrics speak volumes to its potential worth. Although its cash flow statement—marked by significant swings such as the operating cash flow at over negative $6.7M—paints a challenging picture, this financial volatility is not foreign to companies in the medical innovation field.

A unique point in Relmada’s financial tapestry is its balance sheet, showing remarkable leverage with a debt-to-equity ratio touching zero, offering a glimpse into the careful financial strategy they’re maneuvering, amidst bold new ventures. Despite trudging through minor revenue channels, the lead asset NDV-01 may tip the revenue scales in coming quarters, supported by keen investor interest and an upbeat market sentiment tied to its quick and adaptable bladder cancer solution.

Innovation Fuels Market Excitement

The stock market has been abuzz since the announcement of the promising NDV-01, and this chatter has echoed throughout the floors of stock exchanges. Late entrant news from Lucid Capital places it in a prominent spotlight. Rave assessments spark investor enthusiasm, with NDV-01’s clever design and quick operational features amplifying its intrigue.

A pharmaceutical change is anticipated as RLMD positions itself on an upward trajectory, boosted by Lucid Capital’s targeted insights shared on Mar 02, 2026. Investors seem reassured by clear signals of value backing this biotech venture, leaving many to closely examine stock charts, looking out for pivotal rally moments influenced by new revelations and public debates around health sector stocks.

More Breaking News

Conclusion: A Bright Outlook

In review, Relmada Therapeutics seems propelled by its creative pipeline, spearheaded by NDV-01. Despite tightrope walking on the financial front, the pathways it etches in cancer care might just be the wind in its sails. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” This quote emphasizes the importance of financial stewardship within the trading community, particularly relevant as Relmada navigates its fiscal challenges. The bond between business worth and a strategic approach to patient care becomes more intertwined as LUCMD heralds this promising canvas. Traders may find the stock’s recent upswing a hint of the revitalized energy within this innovative enterprise. The vigilance shown by upbeat stakeholders amid market scenarios hints at the splash RLMD envisages in its medicinal strides forward.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RLMD

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”